Emerald Advisers LLC Purchases 41,000 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Emerald Advisers LLC raised its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 10.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 416,866 shares of the biotechnology company’s stock after purchasing an additional 41,000 shares during the period. Blueprint Medicines comprises 1.4% of Emerald Advisers LLC’s portfolio, making the stock its 16th biggest position. Emerald Advisers LLC’s holdings in Blueprint Medicines were worth $36,359,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of BPMC. Swiss National Bank raised its position in Blueprint Medicines by 1.6% during the 3rd quarter. Swiss National Bank now owns 116,200 shares of the biotechnology company’s stock valued at $10,748,000 after purchasing an additional 1,800 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Blueprint Medicines during the 3rd quarter valued at $475,000. Advisors Asset Management Inc. raised its position in Blueprint Medicines by 17.6% during the 3rd quarter. Advisors Asset Management Inc. now owns 5,054 shares of the biotechnology company’s stock valued at $467,000 after purchasing an additional 756 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in Blueprint Medicines during the 3rd quarter valued at $6,465,000. Finally, Intech Investment Management LLC bought a new stake in Blueprint Medicines during the 3rd quarter valued at $1,712,000.

Blueprint Medicines Stock Up 0.3 %

Blueprint Medicines stock opened at $88.72 on Friday. Blueprint Medicines Co. has a fifty-two week low of $80.68 and a fifty-two week high of $121.90. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. The company has a market cap of $5.67 billion, a PE ratio of -82.15 and a beta of 0.58. The business’s 50-day simple moving average is $99.47 and its two-hundred day simple moving average is $93.88.

Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Equities analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Insider Buying and Selling

In related news, insider Ariel Hurley sold 3,203 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the sale, the insider now directly owns 18,270 shares of the company’s stock, valued at $1,692,167.40. This trade represents a 14.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey W. Albers sold 5,000 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $102.28, for a total value of $511,400.00. Following the sale, the director now directly owns 157,557 shares in the company, valued at approximately $16,114,929.96. This trade represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,334 shares of company stock valued at $3,103,512 over the last ninety days. Company insiders own 4.21% of the company’s stock.

Wall Street Analysts Forecast Growth

BPMC has been the subject of several recent research reports. Wedbush reissued an “outperform” rating and issued a $128.00 price target on shares of Blueprint Medicines in a research report on Friday, February 28th. Morgan Stanley initiated coverage on Blueprint Medicines in a research report on Thursday. They issued an “equal weight” rating and a $100.00 price target for the company. Wolfe Research initiated coverage on Blueprint Medicines in a research report on Tuesday, March 18th. They issued an “outperform” rating for the company. Stephens reissued an “overweight” rating and issued a $140.00 price target on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a research report on Friday, February 14th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $124.95.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.